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Androgen receptors are expressed by all stages of growing follicles, and follicular
fluid androgen levels are positively correlated to granulosa cell androgen receptor and
follicle-stimulating hormone (FSH) receptor expression. Thus, androgens may promote
follicular growth, accumulation and/or responsiveness to gonadotropins. This is explored
therapeutically in the concept of androgen priming, to improve the ovarian response
to stimulation in assisted reproduction. Androgen effects may be achieved in two
different ways, either directly by providing exogenous androgen or by providing luteinizing
hormone (LH) activity [i.e., LH or human chorionic gonadotropin (hCG)] to stimulate local
ovarian production of androgen. The androgen concentrations in follicular fluid by far
exceed the levels in female circulation and it has recently been shown that there was
no correlation between serum testosterone levels and follicular fluid androgen levels.
There is some evidence that administration of exogenous dehydroepiandrosterone or
testosterone increases live birth rates, but an optimal protocol has not been established
and such adjuvant treatment should be considered experimental. Furthermore, studies
exploring long-term administration of LH activity, achieving LH levels comparable to those
seen in women with polycystic ovary syndrome, are awaited. The aim of the present
review is to discuss critically the most suitable approach for androgen priming from
a biological and clinical standpoint, and to evaluate current approaches and results
obtained in clinical trials.
Keywords: androgen priming, testosterone, follicular responsiveness, follicular recruitment, local androgen
production, LH activity, IVF
CAPSULE
Androgen priming has a biological basis for improving poor response during ovarian
stimulation. While administration of exogenous androgens may have effects on early stages of
follicle development, they are unlikely to affect the androgen concentrations in more mature
follicles. Conversely, administration of hormones that increases the intra-follicular androgen
concentration may have effects across a broader range of stage of follicle development.
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INTRODUCTION
Androgens play key roles in a range of reproductive functions
necessary for conception, acting directly through the androgen
receptor (AR), or as necessary precursors for estrogen synthesis.
Androgens are considered to represent a double-edged sword in
human follicular development, with positive effects on follicles
at preantral and small antral stages and potential negative effects
on pre-ovulatory follicles unless appropriate downregulation of
granulosa cell AR takes place (1, 2).Womenwith polycystic ovary
syndrome (PCOS) are characterized by a high antral follicle count
and increased androgen levels, and androgens seem to play an
important role in aberrant follicle development and anovulation
in this group of women (3, 4). The pathophysiology of PCOS
is however complex: although testosterone levels in small
follicles from women with PCOS are increased and luteinized
granulosa cells showed significantly increased transcripts of
FSHR in PCOS, CYP19 expression is reduced, thus the follicular
hyperandrogenism downregulates conversion to estrogen (5, 6);
these alterations may impact on oocyte quality (7). Conversely,
androgens may enhance follicular responsiveness to FSH by an
upregulation of granulosa cell FSH receptor (FSHR) expression.
In human small antral follicles (3–9mm) a positive correlation
between granulosa cell FSHR expression and both follicular
fluid androgen levels and granulosa cell AR expression was
demonstrated (8). Thus, at early stages, androgens may promote
follicle growth, and this might be exploitable therapeutically.
In the human ovary, AR gene expression has been detected
in preantral follicles from the primary stage onwards (9) and
in antral follicles peaking at ∼6mm (10). AR protein has
been observed in follicles from the primordial stage, gradually
increasing during follicle development so that it is present in
all multi-layered preantral follicles (2, 11). The duration of
follicular growth from the multi-layered preantral stage to the
stage where cyclic recruitment toward dominance and ovulation
occurs (antral follicles of 2–5mm) is estimated to last ∼70 days
(12). Therefore, this period may include developmental stages
where follicles are sensitive to androgens, which may result in
increased granulosa cell FSHR expression thus enhancing the
number of follicles responding to exogenous FSH administration.
One of the most challenging groups of patients in infertility
treatment is women with diminished ovarian reserve (DOR),
who only develop a limited number of follicles after ovarian
stimulation (OS) and have reduced chances of becoming
pregnant (13). This group of patients is becomingmore prevalent
due to general societal changes in postponing childbearing.
The possibility of developing improved stimulation protocols
to increase the number of oocytes harvested following OS
in such patients has received huge interest and investigation
in recent years. Androgen priming in women with DOR has
been investigated, but without consensus on how it should be
performed or indeed whether it is an effective approach.
The aim of the present review is to discuss critically the
most suitable approach for androgen priming based on a
biological rationale, and to evaluate current approaches and
results obtained in clinical trials.
BIOLOGICAL RATIONALE OF ANDROGEN
PRIMING
The widespread expression of AR in the ovary (2) indicates a
likely range of actions and complicates interpretation of specific
effects of androgens on follicular development. In AR knock
out (ARKO) studies in rodents, global AR-null mice showed
aberrant folliculogenesis with lower numbers of antral follicles
and fewer oocytes after stimulation, they were sub-fertile and
developed premature ovarian insufficiency (14, 15). Mice that
specifically lacked AR expression in the granulosa cells had
affected reproduction similarly to the global ARKO (AR-null
mice) with fewer ovulated oocytes, resulting in 1.6 pups per
litter compared to 6.6 in wildtype (14). Their ovaries contained a
different distribution of follicle classes with fewer antral follicles
but more preantral and atretic follicles as compared to wildtype
mice. Further, in vitro growth of isolated preantral follicles from
ARKO mice were slower than that of wildtype and number of
litters per female was halved as they developed premature ovarian
insufficiency. These studies in mice clearly point to the granulosa
cells as targets of the main androgen effect on ovarian function
and reproductive success and justify focusing on the granulosa
cell as the key target for androgen action in the ovary.
Landmark studies in primates now two decades old
showed that testosterone administration had a pronounced
effect on follicles and granulosa cells after only 3- and
10-days administration (16–19). These studies demonstrated
that granulosa cell AR expression was significantly increased
after testosterone administration and that AR expression was
positively associated with expression of the proliferation-specific
antigen Ki-67 and negatively associated with granulosa cell
apoptosis (17). Testosterone exposure increased the number
of growing follicles (indicating an effect on the earliest
stages of folliculogenesis) and granulosa cell responsiveness to
FSH. Equally important, individual follicles demonstrated a
significant positive association between FSHR and AR mRNA
levels irrespective of testosterone administration. Furthermore,
testosterone administration significantly increased granulosa cell
FSHR expression. It was suggested that testosterone promotes
follicular growth by amplifying the effect of FSH.
In those primate studies testosterone was administered in two
doses (i.e., 4 or 0.4 mg/kg), which when extrapolated to a woman
with a weight of 65 kg would correspond to doses of 260 and
26 mg/day, respectively, which are far beyond the threshold for
inducing virilizing effects in women and therefore not clinically
relevant. By comparison, 5–10mg testosterone/day is required
for physiological replacement in adult men.
Further strengthening the association between FSH sensitivity
and androgens, evaluation of follicular fluid and the associated
granulosa cells from normal human small antral follicles found
highly significant associations between FSHR expression and
both AR expression in granulosa cells and follicular fluid
androgen levels (10). Thus, these data support a close link
between FSHR expression and the action of androgens within
small antral follicles in normal women, and support the
hypothesis that androgens drive normal follicular development,
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and that this occurs across a broad range of stages of
follicle development.
Taken together, there is therefore a clear biological basis for
exploring the concept of androgen priming and the potential of
recruiting an increased number of follicles in respond to OS.
What is less clear is how this androgen priming is best achieved
and how the development of clinical applicable methods should
be addressed.
PRODUCTION OF ANDROGENS AND
EFFECTS OF ANDROGEN IN THE HUMAN
OVARY INCLUDING HUMAN SMALL
ANTRAL FOLLICLES
It is well-established that ovarian androgens are produced by
the theca cells under appropriate stimulation of LH, or hCG.
Androgens are aromatized into estrogens within granulosa cells.
Androgen production is critically dependent on the expression
of the CYP17 enzyme that during a two-step reaction catalyzes
conversion of pregnelonone to DHEA via 17-OH-pregnelonone.
Androstenedione production by human theca cells in vitro was
augmented 20-fold by the presence of inhibin A and insulin-like
growth factor-1 (IGF1) in the culture medium (20). The highest
concentration of inhibin tested was 100 ng/ml, which has now
been shown to be low compared to that found in the follicular
fluid of human small antral follicles (21, 22). Since inhibin A and
inhibin B are only produced by granulosa cells and not the theca
cells, after stimulation with FSH, this clearly demonstrates that
follicular androgen production is under the control of both LH
and FSH, involving an interaction between theca and granulosa
cells in a development of the 2 cell, 2 gonadotrophin model of
follicle function.
Recently, concentrations of Inhibin B in fluid from
normal small antral follicles obtained in natural menstrual
cycles were associated with follicular fluid concentrations
of androgens and to gene expression levels in granulosa
cells (23). Inhibin B concentrations were strongly positively
associated with intrafollicular concentrations of testosterone
and androstenedione and with mRNA levels of FSHR, LHR,
and CYP19, while AR mRNA was not related (23). These data
strengthen the notion that inhibins also play an important role
in the regulation of androgen synthesis in vivo, which then in
turn up-regulates FSHR. Downstream, this upregulates LHR and
aromatase (i.e., CYP 19) expression in granulosa cells.
Recent data suggests that AR expression is under the control
of LH, as in vitro studies on human granulosa cells found a
significant down regulation of AR in the presence of LH (4).
However, LHR only starts to become expressed in granulosa cells
around the time of follicular selection at a diameter of 8–10mm
in normal women, and the regulation of AR expression in earlier
stages of human folliculogenesis has not been described.
CLINICAL ASPECTS OF ANDROGEN
PRIMING
Increased androgen levels may be achieved in two different
ways, either by the administration of exogenous androgen
TABLE 1 | Concentrations of androgens in circulation of women and men as
compared to that of follicle fluid in human small antral follicles with a diameter of
3−9 millimeter (N = 545 for testosterone and N = 285 for androstenedione).
Testosterone Androstenedione
(nmol/L) (nmol/L)
Women pre-menopausal* 0.5–1.5 5–9
Men 10–35 3–7
Human follicular fluid (mean; median) 245 [194] 2,361 [2,256]
*Data in circulation from (24).
(i.e., DHEA or testosterone) or by providing hormones that
stimulate enhanced local production of androgen within the
ovaries (i.e., LH or hCG). Alternatively, estrogen production
may be blocked by the administration of an aromatase inhibitor
(AI) causing androgen accumulation. Administration of LH,
hCG, or AI has likely advantages in providing androgen at
its site of physiological production, metabolism and action
with the avoidance of systemic exposure thus preventing or
minimizing side-effects. Androgen concentrations in human
follicular fluid, reflecting the physiological levels that granulosa
cells and oocytes are exposed to, are much higher than in the
circulation (Table 1). In antral follicles of 3–12mm, the follicular
fluid concentrations of testosterone and androstenedione are
200–350 nmol/L and 2,000–3,800 nmol/L, respectively (Table 2)
(21). The concentration of testosterone in the circulation in pre-
menopausal women is around 1 nmol/l, while it is 20 times
higher in the circulation of men with symptoms of androgen
deficiency occurring in men below ∼10 nmol/l. For comparison,
the intratesticular concentration of testosterone is around 1,000
nmol/l (25).
Collectively, these data suggest that exogenous administration
of testosterone is unlikely to affect follicular fluid concentrations
of androgens to which granulosa cells are physiologically
exposed without inducing virilizing side-effects. Additionally,
high doses of testosterone will exert negative feedback effects
on gonadotrophin secretion, which will certainly impact follicle
development and function.
To support the notion that that administration of exogenous
androgens acting through the systemic circulation would exert
little if any effect on the local intrafollicular environment
affecting granulosa cells, it was recently shown that there was no
correlation between serum testosterone levels and follicular fluid
follicular fluid testosterone, DHEA, estradiol or anti Müllerian
Hormone (AMH) concentrations (26). This confirms that
intrafollicular sex-steroid concentrations in individual follicles
are unlikely to be affected via the circulation.
EFFECT OF ANDROGEN ADMINISTRATION
IN FEMALE TO MALE TRANSGENDER
PATIENTS
Female to male transgender patients receive masculinizing
doses of testosterone, which result in both physical and
psychological effects (27, 28). These patients are often treated
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TABLE 2 | Distribution of testosterone and androstenedione concentrations in fluid from human small antral follicles with a diameter between 3 and 10mm obtained in
women between 17 and 43 years of age (N = 545 for testosterone and N = 285 for androstenedione).
Testosterone concentration (nmol/L)
Testosterone(nmol/l) <50 50–100 100–200 200–300 300–400 400–500 500–600 >600
No. follicles 37 91 171 100 75 50 21 33
% follicles 7 17 31 18 14 9 4 6
Androstenedione concentration (nmol/L)
Androstenedione (nmol/l) <100 100–500 500–1,000 1,000–1,500 1,500–2,000 2,000–3,000 3,000–4,000 >4,000
No. follicles 4 23 33 41 26 66 56 36
% follicles 1 8 12 14 9 23 20 13
with around 200mg testosterone intramuscularly every 2nd week
or testosterone gels delivering 5–10mg daily (27). These doses are
sufficient to stop menstrual cycles and in some studies the ovaries
have been described as having a polycystic ovary morphology
(PCOM) (29–31). When compared to ovaries from regularly
cycling women, the ovaries of transmen were enlarged, with
a 2-fold increase in the number of cystic antral follicles, 3.5-
fold increase in atretic follicles, a collagenized 3-fold thicker
cortex, hyperplasia of the theca interna and stroma, and clusters
of luteinized stromal cells (31). However, in a recent paper,
the prevalence of PCOM was not significantly increased after
long-term treatment of transmen with testosterone (32). This
undoubtedly results from direct effects on the ovaries but is
complicated by endocrinological effects on the pituitary with
reduced secretion of LH and FSH. This group of patients
clearly demonstrate that androgen priming with administration
of exogenous testosterone in low-responder women may have
complex ovarian and systemic effects, and it may be difficult to
determine a dose that provides additional recruitment of follicles
without inducing unwanted side effects elsewhere in the body.
CLINICAL TRIALS INVESTIGATING
ANDROGEN PRIMING BY USE OF
EXOGENOUS ANDROGENS
Dehydroepiandrosterone sulfate (DHEAS), DHEA,
androstenedione, testosterone and dihydrotestosterone (DHT)
are the primary circulating androgens in women of reproductive
age. Only testosterone and DHT are potent androgens, whereas
the others are precursors that require conversion in order to
exert stronger androgenic effects (33).
DHEA is a precursor of both testosterone and estradiol. It is
produced in the adrenal Zona Reticularis (50%), ovarian stromal
cells (20%), and from conversion of DHEAS (30%). DHEA is
a weak partial agonist of the AR. It exerts androgenic effects
via conversion into androstenedione and testosterone. It is also
a prohormone in the synthesis of estrogens via conversion by
aromatase of testosterone and androstenedione to estrone and
estradiol (34).
Gleicher et al. (35) proposed that some forms of DOR could
be caused by “adrenal hypoandrogenism.” Patients with DOR
and adrenal hypoandrogenism are generally younger and have
low-normal levels of DHEA. In contrast, they proposed that
older women with DOR can have what they termed functional
hypoandrogenism due to reduced conversion of DHEA to
testosterone by the theca cells. Their serum DHEA levels are
increased due to reduced conversion. They hypothesize that the
patient most likely to respond to DHEA supplementation will
be the former, younger patient with adrenal hypoandrogenism,
whereas the latter might benefit more from supplementation
with testosterone. This has not, however, been confirmed,
and the potential diagnosis of “adrenal hypoandrogenism” is
unclear (35).
DHEA
DHEA is widely used as pretreatment for low responders
undergoing IVF in order to increase the number of growing
follicles. A Cochrane review in 2015 investigated the effect of
DHEA supplementation on IVF outcome. This meta-analysis
showed a small positive effect on clinical pregnancy rate [Odds
ratio (OR) 1,34; CI 1.01–1.76, 12 randomized controlled trials
(RCTs)] and live birth rate (OR 1.81; CI 1.25–2.62, 8 RCTs).
A funnel plot gave no indication of publication bias (36). The
most recent RCT of DHEA supplementation for IVF is from
2016. These studies are summarized in Table 3. However, the
patients included are heterogeneous between studies; they varied
from infertile women with normal ovarian reserve markers
to older women with severe DOR. It is possible that DHEA
supplementation might be beneficial in subgroups of women
with DOR, but DHEA adjuvant treatment should be considered
experimental. Currently, a further RCT investigating adjuvant
DHEA (DITTO study) is awaited.
Testosterone
The aim of using testosterone as an adjuvant treatment in women
with a low ovarian reserve undergoing OS is to increase the
number of follicles which are sensitive to gonadotropin and
thereby achieve more mature follicles, more collected oocytes,
and thus increase the pregnancy and live birth rates.
Exogenous testosterone for androgen priming is usually
applied either transdermally by administration of a testosterone
gel (most frequently) or a patch, or through oral capsules. The
doses and duration of treatment varies between studies. A recent
systematic review and meta-analysis of 7 RCTs including women
with a poor ovarian response undergoing IVF published from
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TABLE 3 | Outcome of RCTs in which DHEA was used for supplementation in IVF treatment.
Study Design No. of patients DHEA regime Conclusion clinical pregnancy
Artini et al. (37) DHEA vs. no
co-treatment
24, poor responders,
Bologna criteria, age 31–42
Daily oral DHEA 25mg × 3 daily, starting 3
months prior to IVF
DHEA 3/12 vs. control 2/12
Divita et al. (38), conference
abstract only
DHEA vs. placebo 31, infertile, poor
responders, age?
Daily oral 40mg micronized DHEAS,
starting CD 21 in previous cycle, GnRH
agonist protocol
DHEA 7/16 vs. control 5/15
Evans et al. (39), conference
abstract only
DHEA vs. placebo 41 Poor responders Daily DHEA oral 75mg × 1, for 4 months
prior to IVF
DHEA 1/21 vs. control 1/20
Live Birth: DHEA 0/21 vs.
control 1/20
Jindal et al. (40), conference
abstract only
DHEA vs. no
co-treatment
406, poor responders Daily micronized DHEA oral 75mg for up
to 6 months, combination of GnRH
agonist and antagonist cycles
DHEA 39/203 vs. control 20/203
Live Birth: DHEA 35/203 vs.
control 17/203
Kara et al. (41) DHEA vs. no
co-treatment
208, diminished ovarian
reserve
Daily oral DHEA 25mg × 3 daily, starting 3
months prior to IVF
DHEA 33/104 vs. control 34/104
Moawad et al. (42) DHEA vs. no
co-treatment
133, poor responders Daily oral DHEA 25mg × 3 daily, starting 3
months prior to IVF
DHEA 12/67 vs. control 8/66
Live Birth: DHEA 11/67 vs.
control 7/66
Tartagni et al. (43) DHEA vs. placebo 52 infertile but not poor
responders
Daily DHEA oral 75mg × 1, starting 8
weeks before IVF
DHEA 10/26 vs. control 7/26
Live Birth: DHEA 10/26 vs.
control 4/26
Tartagni et al. (44) DHEA vs. placebo 109 infertile, undergoing first
IVF cycle
Daily DHEA oral 75mg × 1, starting 8
weeks before IVF
DHEA 22/53 vs. control 18/56
Live Birth: DHEA 22/53 vs.
control 13/56
Wiser et al. (45) DHEA vs. no
co-treatment
33, diminished ovarian
reserve
Daily oral DHEA 75mg × 1 for at least 6
weeks prior to IVF
DHEA 4/17 vs. control 2/16
Live Birth: DHEA 3/17 vs.
control 1/16
Yeung et al. (46), conference
abstract only
DHEA vs. placebo 72, normal responders Daily DHEA oral 25mg × 3, 12 weeks
prior to IVF
DHEA 10/36 vs. control 15/36
Live Birth: DHEA 7/36 vs.
control 11/36
Yeung et al. (47) DHEA vs. placebo 32, expected poor response Daily DHEA oral 25mg × 3, 12 weeks
prior to IVF
DHEA 3/16 vs. control 4/16
Live Birth: DHEA 2/16 vs.
control 2/16
Zhang et al. (48) DHEA vs. no
co-treatment
105, dimished ovarian
reserve
Daily DHEA oral 25mg × 3, 12 weeks
prior to IVF
DHEA 8/52 vs. control 7/53
Kotb et al. (49) DHEA vs. no
co-treatment
140, poor responders,
Bologna criteria
Daily DHEA oral 25mg × 3, 12 weeks
prior to IVF
DHEA 20/70 vs. control 9/70
Other non-RCTs on DHEA supplementation are listed in this table
Study Design No. of patients DHEA regime Conclusion
Barad et al. (50) Case-Control 165, diminished ovarian
reserve
Daily DHEA oral 25mg × 3, up to 4
months prior to IVF
DHEA 13/64 vs. control 11/101
Xu et al. (51) Retrospective
cohort study
386, poor responders
according to Bologna
Criteria
Daily DHEA oral 25mg × 3, 12 weeks
prior to IVF
DHEA 57/189 vs. control 37/197
Vlahos et al. (52) Prospective cohort
study
161, poor responders Daily DHEA oral 25mg × 3, 12 weeks
prior to IVF
DHEA 1/48 vs. control 8/113
Chern et al. (53) Retrospective
cohort study
151 poor responders,
Bologna Criteria
90mg oral DHEA daily. DHEA 16/67 vs. control 6/84
Live Birth: DHEA 12/67 vs.
control 5/84
2006 to 2018 found that treatment with testosterone increased the
number of oocytes collected and most importantly the live birth
rate (RR 2.29, 95% CI 1.31–4.01, p = 0.004), with low statistical
heterogeneity between the included studies (54).
The testosterone doses used in the treatment arms of the 7
RCTs were 10–25 mg/day (gel) (55–58), 2.5 mg/day (patch) (59),
or 40 mg/day (oral capsules) (60). The timing and the duration of
the testosterone treatment varied from five to 51 days preceding
OS, or only during the rFSH stimulation period in one pilot
RCT (61).
Despite the use of androgens as an adjuvant for OS being off
label, it is used by many physicians for treatment of women with
a DOR (62), and the range of protocols identified (54) indicates
that the evidence for the use of priming with testosterone before
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OS is not robust. The ongoing T-TRANSPORT trial investigates
if 5.5mg testosterone/day (gel) for 2 months as a pretreatment
to OS will result in more pregnancies compared to placebo in
women with DOR (63). The safety of these relatively high doses
also needs to be established.
CLINICAL TRIALS INVESTIGATING
ANDROGEN PRIMING BY USE OF HCG,
LH, OR AIS
A concept of short-term local, intra-ovarian “androgen priming”
before OS was developed and investigated in expected normal
responder women with regular menstrual cycles (64, 65). HCG
(LH activity) and an AI were administered to achieve a temporary
enhancement of local androgen exposure (within the follicles)
before OS. Early follicular phase down-regulation using a GnRH-
antagonist was applied from cycle day (CD) two and during the
priming period, before initiation of OS with gonadotropins, to
inhibit development of a dominant follicle. The control group
received only the GnRH antagonist during the priming period.
The treatment regimen was successful in raising intrafollicular
androgen levels in pre-ovulatory follicular fluids collected during
oocyte retrieval almost 2 weeks after cessation of the priming
period, with significantly higher testosterone levels compared to
controls [26.4 nmol/l (95%CI 24.6–27.6) vs. 22.4 nmol/l (95%CI
19.3–22.4), p = 0.014] (65). Furthermore, the proportion of
the antral follicle count on CD2 that reached the preovulatory
state, and the serum estradiol level per preovulatory follicle, were
higher in the priming group in the larger study, however, no real
clinical benefit was observed (65).
Another group performed an RCT (n = 147) including
pretreatment with rLH for seven days (300 IU per day)
administered during GnRH-agonist downregulation in the long
protocol just before initiation of rFSH stimulation (66). The rLH
pretreatment significantly increased the number of small antral
follicles, as compared to the untreated group. At stimulation
day one, the plasma LH level was significantly higher in the
rLH pretreatment group, but estradiol and testosterone levels
were similar between groups, then and at stimulation day 8.
Significantly more fertilized embryos were seen in the rLH
pretreated group as well as a trend toward more high-grade
embryos. The ongoing pregnancy rate was similar. Follicular fluid
analyses were not performed.
In the above-mentioned studies expected normal responders
with regular menstrual cycles rather than poor-responders were
included, and androgen priming was used in the short-term
(days) rather than long-time (weeks to months).
Bercaire and coworkers (67) investigated an “ANDRO-IVF
protocol” including a 24-days pretreatment in poor responder
patients (n = 13) who had undergone a failed IVF cycle,
which was later used as the control. From CD one transdermal
AndroGel(r) (67) 25mg every other day, oral letrozole 2.5mg
daily, and hCG 2500 IU subcutaneously twice a week were
administered. Cycle control was performed with estradiol
valerate from CD three to CD 15 followed by micronized
progesterone from CD 15 to CD 24, followed by a new menstrual
cycle, in which high dose OS and IVF took place. They reported a
significantly lower cancellation rate, a higher number of oocytes
and metaphase II oocytes, a higher fertilization rate and a higher
number of embryos per patient and concluded that the protocol
seemed to improve clinical outcomes. However, the small sample
size, the use of higher daily gonadotropin doses and longer
duration of OS, as well-including failed cycles only as controls
(with a known tendency of regression toward the mean) limit
firm conclusions, and as the authors state, further RCTs are
needed (67).
Supplementation with hCG activity or aromatase inhibitors
during OS for IVF has also been explored. Different doses of
hCG (0–150 IU daily) during rFSH stimulation were explored
in an RCT using the long GnRH agonist protocol (68). Patients
were stratified into three groups according to the concentration
of serum hCG at steady state at Day 6 of stimulation (< 3.5 IU/l,
3.5–8.0 IU/l and>8.0 IU/l), and themean numbers of top-quality
embryos were 0.5+0.9, 1.1+1.8, and 1.5+1.5, respectively (P =
0.03). Cumulative live birth rates including subsequent frozen
embryo replacement (FER) cycles were similar, but the study
was not powered to detect potential differences in pregnancy or
delivery rates.
Following a long GnRH agonist protocol, OS with Highly
Purified human Menopausal Gonadotropin (HP-hMG)
containing hCG activity (∼30 IU/day) was compared to
rFSH in an RCT (69). Among the HP-hMG-treated patients,
those with the highest day 6 hCG levels had the highest ongoing
pregnancy rates. Also, the number of top-quality embryos and
the proportion of patients with top-quality embryos in the HP-
hMG group were positively correlated with circulating levels of
hCG. The fertilization rate was similar in the HP-hMG and rFSH
group, but the proportion of top-quality embryos was higher
with HP-hMG. The serum level of hCG and androgens were
higher at day 6 and at the end of stimulation in the HP-hMG
group as were the levels in pre-ovulatory follicular fluid.
The use of an AI during OS for IVF treatment was included
in a recent Cochrane review (70). There was no conclusive
evidence indicating that treatment with letrozole with or without
gonadotropins differed from gonadotropins alone in GnRH-
agonist or antagonist protocols with respect to effects on live-
birth or pregnancy rates, either in the general population
of women undergoing IVF treatment or in poor responders.
Larger, high-quality RCTs are needed to reach a firm conclusion
as to whether this approach should be adopted into routine
clinical practice.
LONG-TERM LOW DOSE HCG PRIMING:
LOCAL INCREASED ANDROGEN LEVELS
It can be argued that, albeit simplifying the complex
pathophysiology of the condition, women with PCOS experience
long-term androgen priming with increased endogenous
concentrations of LH that result in multiple small antral
follicles, which may be recruited in response to OS with
gonadotropins and result in the well-known excessive response
that characterizes these patients. Potentially, a long-term
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low dose hCG administration could result in a phenotype
resembling PCOS at least in terms of an increased recruitment
(or accumulation) of small antral follicles, which could lead to an
increased harvest of mature oocytes in response to OS. Thus, the
concept of creating a reversible PCO-like condition could be of
interest in connection with poor responder women.
A first attempt to achieve this has recently been published (71)
in which low responder women (n = 30) received 260 IU hCG
every 2nd day for 8 weeks to augment intra-ovarian androgen
levels. Simultaneously women received 2.5mg letrozole daily to
prevent androgens from being converted into estrogens, and in
addition women were down regulated with a GnRH agonist to
prevent FSH from rising in response to low levels of estradiol.
Priming stopped on the 1st day of OS. The primary endpoint
was circulating concentration of AMH after 8 weeks of priming,
while secondary endpoints included antral follicle count (2–
10mm), and serum hCG, testosterone and progesterone levels
(71). However, the intervention did not produce any significant
improvements, and the resulting androgen production was
lowered compared to the natural situation. This is likely to be
because the administration of hCG was unable to overcome
the lowering of gonadotropin levels caused by GnRH agonist
administration. Further studies addressing this issue need to
explore other androgen priming protocols and their clinical value
in IVF.
CONCLUSIONS
In the human ovary, AR is expressed from the primary
and primordial stage onwards with all multi-layered preantral
follicles expressing AR, thus androgens are likely to have
important physiological roles at all stages of folliculogenesis.
The positive correlation between follicular fluid androgen levels
and granulosa cell FSHR expression indicates that androgens
promote follicular responsiveness to FSH. There is some
experimental evidence to support this, in addition to the
recognized hypersensitivity to exogenous FSH of women with
PCOS, but the difficulties of studying human folliculogenesis
mean that many questions regarding the roles of androgens
in the ovary remain unanswered. It is important to recognize
that androgen concentrations in follicular fluid by far exceed
the levels in the female circulation, thus while exogenous
administration of androgens may have effects on early stages
of follicle development, it is unlikely to affect concentrations of
androgens in more mature follicles. Conversely, administration
of hCG or an AI does increase intra-follicular androgen
concentration and may have effects across a broader range
of stage of follicle development. Current clinical evidence
regarding administration of exogenous DHEA or testosterone
seems to increase live birth rates, but more robust studies
are required to confirm this, and optimize protocols: at
present, such adjuvant treatment should therefore be considered
experimental. Currently, two RCTs investigating adjuvant DHEA
(DITTO study) and transdermal testosterone (T-TRANSPORT)
are awaited and their results will shed light on this potential
therapeutic approach.
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